ANRS 0144S COVICOMPARE-GUINEE
Phase II trial evaluating the immunogenicity and safety of the BBIBP-CorV vaccine in adults in Guinea.
Last updated on 27 March 2024
Primary objective
To assess the effect of BBIBP-CorV vaccine on the humoral immune response in adults, one month after full vaccination for SARS-CoV-2.
Theme
SARS-CoV-2
Status
Ongoing study
If you wish to access biological samples from this study:
Samples from the ANRS MIE BioBank are made available after the request is approved either by the Scientific Advisory Board if the study is ongoing, or by the Director of the ANRS MIE if the study has been completed.
For all requests, please fill in the form below and send it to the following address biobanque@anrs.fr